Option chain shows key data for AEye's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for AEye.

AEye (NASDAQ:LIDRW) Stock, Option Chain

AEye Inc is a provider of high-performance, active lidar systems for vehicle autonomy, driver-assistance systems (ADAS), and robotic vision applications. The company's software-definable 4Sight Intelligent Sensing Platform combines solid-state active lidar, an optionally fused low-light HD camera, and integrated deterministic artificial intelligence to capture more intelligent information with less data, enabling faster, more accurate, and more reliable perception of the surroundings. Majority of the Company's revenue is generated from customers located in the United States followed by Europe, and Asia-Pacific.

AEye Inc

RBC Capital analyst Scott Hanold maintains Chord Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRD#NASDAQ">CHRD</a>) with a Outperform and lowers the price target from $185 to $180.

News

Price Target

Analyst Ratings

CHRD

RBC Capital Maintains Outperform on Chord Energy, Lowers Price Target to $180

Village Farms International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) and Hemp for Victory filed a joint motion seeking to disqualify the Drug Enforcement Administration (DEA) from defending the proposed rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act.
The parties argue that the DEA is compromised and opposes the rescheduling, suggesting its role should be taken by the Department of Justice (DOJ) to ensure an impartial process.
"It is our belief that the DEA cannot lawfully act as the proponent of the Proposed Rule and that its actions throughout the administrative process demonstrate that it opposes the proposed transfer of marijuana to Schedule III and is therefore compromised," Shane Pennington, partner at Porter Wright Morris &amp; Arthur, LLP and counsel to Village Farms and Hemp for Victory commented, "Treating the DEA as the proponent of the Proposed Rule would violate APA and DEA regulations and render these proceedings a sham. Lawyers from the Department of Justice, not the Drug Enforcement Administration, must therefore defend this rule."
In August 2023, Health and Human Services (HHS) Secretary Xavier Becerra confirmed his agency responded to President Biden&#8217;s directive to provide scheduling recommendations for cannabis to the DEA. HHS <a href="https://www.benzinga.com/markets/cannabis/23/08/34126690/hhs-secretary-confirms-it-is-recommending-cannabis-be-rescheduled-per-bidens-directive">called for marijuana to be reclassified as a Schedule III drug</a> under the Controlled Substances Act.
The <a href="https://villagefarms.com/wp-content/uploads/2024/11/Hemp-for-Victory-and-Village-Farms-Motion-to-Disqualify-and-Supplement-Record-with-Exhibits-A-C.pdf">motion</a> argues that "Not once in its history as an agency had DEA ever rejected an HHS scheduling recommendation. This time, however, DEA did not just disagree with HHS's views, it opposed them so vehemently that the Attorney General had to refer the interagency dispute to the Office of Legal Counsel for resolution."
Read Also: <a href="https://www.benzinga.com/general/health-care/24/11/42077935/trump-picks-dr-oz-who-says-seniors-should-give-medical-marijuana-a-try-to-lead-centers-for-medicare-and-medicaid-services">Trump Picks Dr. Oz, Who Says Seniors Should Give Medical Marijuana A Try, To Lead Centers For Medicare And Medicaid Services</a>
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h2 class="wp-block-heading">Calling For Transparency</h2>
The motion also asks that the record include all requests for hearing and/or participation in these proceedings filed with the DEA; a record of the decisions made by the Administrator regarding why certain parties were designated as participants and others were not; and any ex parte communications between DEA and third parties.
"Without knowing who DEA excluded and why, there is no way to assess whether and to what extent the Agency's decisions are arbitrary and capricious, the subject of bias, or otherwise unlawful," reads the filing. "If, for example, DEA included parties with expertise on a particular topic but only if they opposed the Proposed Rule while also excluding parties with even more expertise on that same topic if they supported the Proposed Rule, then there would be a powerful case to be made that the Agency's decisions were arbitrary and capricious."
Among 25 participants that DEA chose to join the hearing on rescheduling cannabis is Smart Approaches To Marijuana (SAM), an organization opposed to marijuana legalization and commercialization. On the other hand, Village Farms is <a href="https://www.benzinga.com/markets/cannabis/24/11/41726679/village-farms-is-only-cannabis-operator-selected-to-represent-weed-industry-at-dea-rescheduling-">the only cannabis operator selected to represent cannabis industry</a>.
Village Farms and Hemp for Victory also require that SAM and the DEA be ordered to preserve their records, as factual evidence demonstrates unlawful conduct which has further compromised the DEA's participation in the proceedings.
Michael DeGiglio, retired Navy captain and naval aviator and president and chief executive officer of Village Farms concluded, "Our organization embraces the power of the cannabis plant as an alternative to Big Pharma and harmful, addicting drugs like opioids. However, we continue to face burdensome challenges in several of our regulatory jurisdictions that not only restrict us from advancing access to cannabis for millions of people, but have also created near-insurmountable institutional barriers to clinical research involving cannabis. We are proud to be one of the pro-cannabis participants selected to testify as a witness in the upcoming Rescheduling Hearing, but the filing of this joint motion reflects our desire for a more transparent process that ensures all credible voices are heard, including other applicants whose expertise has been overlooked or ignored."
<h2 class="wp-block-heading">DEA Under Attack</h2>
The motion follows a lawsuit by a Washington-based researcher filing a <a href="https://www.benzinga.com/news/legal/24/11/41923948/dea-faces-lawsuit-alleging-bias-in-marijuana-rescheduling-process">lawsuit against the DEA alleging multiple legal violations</a> in the agency&#8217;s process of <a href="https://www.benzinga.com/topic/cannabis-rescheduling" target="_blank" rel="noreferrer noopener">rescheduling marijuana</a>. David Heldreth, CEO of psychedelic research firm Panacea Plant Sciences, claims the DEA&#8217;s recent actions violate federal law and constitutional principles. Despite submitting a request to participate in the hearings, Heldreth&#8217;s company, Panacea Plant Sciences, was excluded from the list of 25 participants chosen by Milgram. This exclusion is at the heart of Heldreth&#8217;s lawsuit, which accuses the DEA of bias and of sidelining critical voices in favor of larger, established players in the industry.
Moreover, the Veterans Action Council (VAC), a cannabis advocacy organization for military vets, <a href="http://drugsense.org/temp/VACXPRESSXXRELEASE_X14XNovemberXX2024.pdf?fbclid=IwZXh0bgNhZW0CMTAAAR1wzl2RC2z5p-kEiG9p4J03gHKGhie0JyDYxWJx3SdVSeDA7a_6WeEXL3Y_aem_ANUFL62rwPZ-jy58Hyw9-A" target="_blank" rel="noreferrer noopener">filed a petition</a> also <a href="https://www.benzinga.com/news/legal/24/11/42068859/veterans-group-challenges-dea-for-seat-at-cannabis-debate-table">challenging its exclusion</a> from the DEA&#8217;s participant list. VAC contends that the DEA failed to meet its obligation to include all interested parties. &#8220;The DEA was tasked with putting forward a group of ‘interested parties.&#8217; They failed to do so, as illustrated by the judge&#8217;s recent order,&#8221; said VAC&#8217;s Michael Krawitz.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/06/39215651/dea-ditches-high-level-federal-health-meeting-on-cannabis-research-another-expression-of-distast">DEA Ditches High-Level Federal Health Meeting On Cannabis Research: Another Expression Of Distaste For Cannabis Rescheduling?</a></li>
</ul>
Photo: Courtesy of RazorMax and ganjaspliffstoreuk to Pixabay

Cannabis

DEA Is Compromised, DOJ Should Replace It In Cannabis Rescheduling, Claims Joint Motion

Leading Domestic Manufacturer and Brewer Continues Ongoing Investments&nbsp;in its Communities, Building on $2 Billion Spend Over Last 5 Years&nbsp;&nbsp;&nbsp;
HOUSTON, Nov. 20, 2024 &nbsp;/PRNewswire/ -- Anheuser-Busch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BUD#NYSE">BUD</a>), a leading domestic manufacturer and brewer of Michelob ULTRA, Busch Light, Budweiser, and Bud Light, today announced a new $14 million investment in its Houston brewery. Over the last 5 years, Anheuser-Busch has invested nearly $2 billion in its facilities across the country to help create and sustain jobs and drive economic prosperity in the communities where it operates and its employees call home.&nbsp;&nbsp;

Contracts

Anheuser-Busch Invests $14M In Its Houston Brewery To Drive Economic Growth; To Help Create And Sustain Jobs And Drive Economic Prosperity In The Communities Where It Operates

Macy&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) shares are trading lower by 3.04% to $14.68 during Wednesday&#8217;s session, reflecting broader retail sector jitters after Target Corporation released disappointing <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">third-quarter earnings</a>.
What To Know: Target missed Wall Street estimates for both revenue and earnings per share, citing cost pressures and challenges related to inventory and supply chain management. The retail giant also lowered its full-year profit outlook, signaling caution heading into the crucial holiday season.
The ripple effects of Target's report are likely weighing on Macy's as investors brace for potential parallels in performance. Target's challenges, such as increased digital fulfillment costs and inventory pressures, may mirror broader trends impacting department stores, which have also been grappling with shifting consumer behavior and rising costs.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42090657/microstrategy-upsizes-convertible-notes-offering-to-2-6-billion-for-bitcoin-purchases">MicroStrategy Upsizes Convertible Notes Offering To $2.6 Billion For Bitcoin Purchases</a>
Additionally, Target's lowered guidance suggests potential headwinds for discretionary spending, a vital revenue driver for Macy's.
Target's results highlighted that while beauty and essentials categories grew, comparable sales across other segments were modest, raising concerns about retail demand. Macy's, heavily reliant on apparel and home goods, is particularly sensitive to shifts in consumer spending priorities. 
The cautious sentiment could pressure Macy's shares as investors reassess retail earnings prospects in a challenging economic environment.
Read Also: <a href="https://www.benzinga.com/tech/24/11/42086154/apple-to-argue-for-dismissal-of-doj-antitrust-case-over-alleged-us-smartphone-market-domination">Apple To Argue For Dismissal Of DOJ Antitrust Case Over Alleged US Smartphone Market Domination</a>
<h2 class="wp-block-heading">How To Buy M Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Macy&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, Macy&#8217;s has a 52-week high of $22.10 and a 52-week low of $14.06.

Why Macy's Stock Is Falling

QCOM

Qualcomm CEO Says Right Now No Large Acquisitions Identified

RBC Capital analyst Steven Shemesh maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a Sector Perform and raises the price target from $290 to $291.

RBC Capital Maintains Sector Perform on Lowe's Companies, Raises Price Target to $291

Trading Ideas

XCUR

Exicure Shares Halted On Circuit Breaker To The Upside, Stock Now Up 82.1%

RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGRY#NASDAQ">SGRY</a>) with a Outperform and lowers the price target from $49 to $35.

SGRY

RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $35

Short Sellers

Rumors

Watching e.l.f. Beauty; Shares Spike Lower, Traders Circulating Unconfirmed Rumors Of A Report On The Company

In a rarely seen legal battle unfolding in a DEA courtroom in Arlington, Virginia, the future of two key psychedelic research compounds, DOI and DOC, hangs in the balance. The DEA's move to classify the substances as <a href="https://www.benzinga.com/topic/federal-schedule-i">Schedule I</a> drugs <a href="https://www.benzinga.com/markets/cannabis/24/07/39975673/dea-faces-backlash-over-psychedelics-ban-proposal-from-student-advocacy-group">has sparked fierce resistance</a> from researchers, neuroscientists and drug policy reform advocates, who argue that such a decision could cripple promising scientific studies.
In late 2023, the <a href="https://www.benzinga.com/markets/cannabis/24/08/40613739/dea-schedules-hearing-on-proposed-ban-of-psychedelics-doi-doc-amid-researchers-concerns">DEA renewed its push</a> to classify DOI and DOC as Schedule I substances, following a previous attempt that was paused in the spring of 2022. While the agency had <a href="https://www.benzinga.com/markets/cannabis/22/08/28654017/deas-latest-proposal-for-psychedelics-banning-gets-archived">withdrawn its original proposal</a>, it signaled intentions to approach the issue with greater strength. Now, the dispute has escalated to an <a href="https://www.benzinga.com/markets/cannabis/24/08/40613739/dea-schedules-hearing-on-proposed-ban-of-psychedelics-doi-doc-amid-researchers-concerns">in-person hearing</a>, the first of its kind since the 1980s when MDMA was added to Schedule I, with many viewing it as a rematch. 
As Psychedelic Alpha <a href="http://reported">reported</a>, the case has attracted little public attention despite the consequences it may have on research. The petitioners, Students for Sensible Drug Policy (SSDP) and neuroscientist Raul Ramos are represented by attorneys Brett Phelps and Robert Rush, who aim to highlight the implications for psychedelic research and public health.
<h3 class="wp-block-heading">Research At Risk</h3>
Opponents of the DEA's proposed scheduling argue that it would severely limit vital research. DOI, in particular, plays a key role in <a href="https://www.benzinga.com/markets/cannabis/24/10/41581443/psychedelic-drug-doi-pinpoints-anxiety-circuits-avoiding-hallucinogenic-effects-study-finds">serotonin-related studies</a>, with scientists relying on it for breakthroughs in medicine. While it faces fewer restrictions as a research chemical, it would be classified as a controlled substance under the federal analogue act if used for human consumption.
David Nichols, a leading figure in serotonin and psychedelic research, testified that classifying DOI as Schedule I &#8220;would be a disaster for public health.&#8221; He and his son Charles Nichols have made major discoveries, including DOI&#8217;s anti-inflammatory properties, which could have broad medical applications beyond psychiatry.
Charles Nichols became interested in DOI after Hurricane Katrina destroyed his lab's supply of chemicals. His father recommended DOI as a substitute, leading to important findings about its anti-inflammatory effects. These discoveries underscore the value of DOI for research, and scheduling it could put an end to promising studies. While <a href="https://www.benzinga.com/topic/psychedelics-research">psychedelics research</a> has focused on mental health, DOI's broader potential could be lost if it is scheduled.
<h3 class="wp-block-heading">Broader Drug Policy Concerns</h3>
While the hearing focuses on the research impact of scheduling DOI and DOC, it also raises broader questions about drug criminalization and the DEA's authority. Alaina Jaster, a neuroscientist at Wayne State University, testified for SSDP and Raul Ramos. A vocal critic of drug criminalization, Jaster shared how her family's struggles with addiction shaped her belief that &#8220;no drug should be criminalized.&#8221; Her testimony highlighted the human cost of the War on Drugs and how such policies often worsen public health issues.
<h3 class="wp-block-heading">The Government&#8217;s Weak Case Against DOI And DOC</h3>
The DEA's case for scheduling DOI and DOC appears flimsy. Their key witness, pharmacologist Theresa Carbonaro, struggled under cross-examination. When asked about law enforcement encounters with DOI or DOC in the past five years, Carbonaro admitted there were none, despite the DEA&#8217;s claim that the drugs were being abused. Her vague explanation—that a lack of evidence doesn&#8217;t rule out abuse—raised doubts about the case&#8217;s credibility.
The DEA&#8217;s report also relied heavily on internet forum posts from sites like Reddit and Erowid, which Carbonaro suggested pointed to emerging abuse trends. However, she couldn't verify the authenticity of these posts or show they were credible evidence of abuse. When asked if any use of DOI or DOC could be considered abuse, Carbonaro answered affirmatively, citing the FDA&#8217;s definition, which limits &#8220;abuse&#8221; to non-medical use of approved substances.
<h3 class="wp-block-heading">What's Next?</h3>
As the hearing enters its second week, SSDP and Ramos&#8217; legal team remain optimistic. Co-counsel Phelps expressed confidence in their evidence and expert witnesses. The hearing is set to conclude by week's end, but the final decision on scheduling DOI and DOC will take several more weeks. Administrative Law Judge Paul Soeffing will review the testimony before submitting his recommendation to the DEA's Chief ALJ, John Mulrooney II, for a final ruling.
Cover image made with AI

Government

Psychedelics

DEA's Case For Scheduling Psychedelics Challenged In Landmark Hearing

Financial giants have made a conspicuous bullish move on Reddit. Our analysis of options history for Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) revealed 16 unusual trades.
Delving into the details, we found 43% of traders were bullish, while 37% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $55,700, and 14 were calls, valued at $748,243.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $60.0 to $170.0 for Reddit over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Reddit's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Reddit's substantial trades, within a strike price spectrum from $60.0 to $170.0 over the preceding 30 days.
<h3>Reddit Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732119384_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$23.6</td>
<td>$21.15</td>
<td>$23.0</td>
<td>$135.00</td>
<td>$230.0K</td>
<td>334</td>
<td align="right">100</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$14.35</td>
<td>$14.3</td>
<td>$14.33</td>
<td>$130.00</td>
<td>$113.2K</td>
<td>1.6K</td>
<td align="right">0</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$54.4</td>
<td>$53.3</td>
<td>$53.3</td>
<td>$80.00</td>
<td>$53.3K</td>
<td>2.6K</td>
<td align="right">20</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$59.5</td>
<td>$58.45</td>
<td>$59.5</td>
<td>$95.00</td>
<td>$47.6K</td>
<td>208</td>
<td align="right">0</td>
</tr>
<tr>
<td>RDDT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$79.5</td>
<td>$79.5</td>
<td>$79.5</td>
<td>$60.00</td>
<td>$39.7K</td>
<td>602</td>
<td align="right">3</td>
</tr>
</tbody>
</table>

<h3>About Reddit</h3>
Reddit Inc is engaged in providing internet content. The company provides online services that include gaming, sports, business, crypto, television and others.
After a thorough review of the options trading surrounding Reddit, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Reddit</h3>
<ul>
<li>With a volume of 2,445,583, the price of RDDT is down -2.3% at $134.0. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 125 days.</li>
</ul>
<h3>Professional Analyst Ratings for Reddit</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $106.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Reddit, targeting a price of $120. 
&#x2A; An analyst from Loop Capital persists with their Buy rating on Reddit, maintaining a target price of $120. 
&#x2A; An analyst from Roth MKM persists with their Buy rating on Reddit, maintaining a target price of $116. 
&#x2A; An analyst from Roth MKM has decided to maintain their Buy rating on Reddit, which currently sits at a price target of $89. 
&#x2A; An analyst from Bernstein persists with their Underperform rating on Reddit, maintaining a target price of $85. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Reddit, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

RDDT

Spotlight on Reddit: Analyzing the Surge in Options Activity

RBC Capital analyst Mike Dahl maintains AZEK Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZEK#NYSE">AZEK</a>) with a Outperform and raises the price target from $46 to $50.

AZEK

RBC Capital Maintains Outperform on AZEK Co, Raises Price Target to $50

Deep-pocketed investors have adopted a bullish approach towards Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Chevron. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 62% leaning bullish and 0% bearish. Among these notable options, 3 are puts, totaling $189,400, and 5 are calls, amounting to $276,320.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $160.0 for Chevron during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Chevron's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Chevron's whale trades within a strike price range from $130.0 to $160.0 in the last 30 days. 
<h3>Chevron Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732119379_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$11.7</td>
<td>$11.55</td>
<td>$11.6</td>
<td>$155.00</td>
<td>$104.4K</td>
<td>728</td>
<td align="right">310</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.55</td>
<td>$8.45</td>
<td>$8.55</td>
<td>$160.00</td>
<td>$96.6K</td>
<td>1.4K</td>
<td align="right">113</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$8.6</td>
<td>$8.5</td>
<td>$8.55</td>
<td>$160.00</td>
<td>$85.5K</td>
<td>1.4K</td>
<td align="right">213</td>
</tr>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.65</td>
<td>$6.65</td>
<td>$160.00</td>
<td>$47.8K</td>
<td>483</td>
<td align="right">72</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$34.95</td>
<td>$33.75</td>
<td>$34.95</td>
<td>$130.00</td>
<td>$38.4K</td>
<td>47</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About Chevron</h3>
Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with production of 3.1 million of barrels of oil equivalent a day, including 7.7 million cubic feet a day of natural gas and 1.8 million of barrels of liquids a day. Production activities take place in North America, South America, Europe, Africa, Asia, and Australia. Its refineries are in the US and Asia for total refining capacity of 1.8 million barrels of oil a day. Proven reserves at year-end 2023 stood at 11.1 billion barrels of oil equivalent, including 6.0 billion barrels of liquids and 30.4 trillion cubic feet of natural gas.
Following our analysis of the options activities associated with Chevron, we pivot to a closer look at the company's own performance.
<h3>Current Position of Chevron</h3>
<ul>
<li>With a trading volume of 1,028,937, the price of CVX is up by 0.3%, reaching $160.08.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 72 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Chevron</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $174.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on Chevron, which currently sits at a price target of $175. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Chevron, targeting a price of $174. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Chevron, which currently sits at a price target of $194. 
&#x2A; An analyst from Truist Securities persists with their Hold rating on Chevron, maintaining a target price of $155. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Chevron, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Chevron Options Trading: A Deep Dive into Market Sentiment

Deep-pocketed investors have adopted a bullish approach towards Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in U usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Unity Software. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 53% leaning bullish and 26% bearish. Among these notable options, 2 are puts, totaling $156,280, and 13 are calls, amounting to $595,173.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $19.0 to $35.0 for Unity Software during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Unity Software's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Unity Software's whale activity within a strike price range from $19.0 to $35.0 in the last 30 days. 
<h3>Unity Software Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732119374_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>U</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.25</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$24.00</td>
<td>$119.2K</td>
<td>289</td>
<td>278</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$3.4</td>
<td>$2.78</td>
<td>$3.3</td>
<td>$24.00</td>
<td>$99.0K</td>
<td>386</td>
<td>302</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$1.26</td>
<td>$1.17</td>
<td>$1.26</td>
<td>$25.00</td>
<td>$57.9K</td>
<td>6.8K</td>
<td>575</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.01</td>
<td>$0.67</td>
<td>$1.01</td>
<td>$35.00</td>
<td>$49.9K</td>
<td>0</td>
<td>495</td>
</tr>
<tr>
<td>U</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$0.46</td>
<td>$0.31</td>
<td>$0.31</td>
<td>$21.50</td>
<td>$46.5K</td>
<td>499</td>
<td>1.5K</td>
</tr>
</tbody>
</table>

<h3>About Unity Software</h3>
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Following our analysis of the options activities associated with Unity Software, we pivot to a closer look at the company's own performance.
<h3>Current Position of Unity Software</h3>
<ul>
<li>Currently trading with a volume of 8,862,640, the U's price is up by 9.19%, now at $21.62. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 96 days.</li>
</ul>
<h3>Expert Opinions on Unity Software</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $19.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Unity Software, which currently sits at a price target of $18. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Unity Software with a target price of $26. 
&#x2A; An analyst from Macquarie has decided to maintain their Underperform rating on Unity Software, which currently sits at a price target of $16. 
&#x2A; An analyst from Wells Fargo downgraded its action to Equal-Weight with a price target of $20. 
&#x2A; An analyst from Benchmark persists with their Sell rating on Unity Software, maintaining a target price of $15. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Unity Software options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on Unity Software Options

Errol Musk, the father of billionaire entrepreneur Elon Musk, recently spoke about his son's new role in Donald Trump's administration, where Elon Musk and Vivek Ramaswamy were <a href="https://www.benzinga.com/news/global/24/11/41927289/trump-appoints-elon-musk-and-vivek-ramaswamy-to-lead-doge-targeting-bureaucracy-and-65-trillion-federal-spending-we-will-not-go-gently">appointed to lead the newly formed</a> "Department of Government Efficiency" (DOGE). The planned presidential advisory commission aims to reduce waste, cut bureaucracy and improve efficiency across federal agencies.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">You can still get 4,000 of its pre-IPO shares for with $1,000 for just $0.25/share</a></li>
<li>With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai-2">Be an early investor with just $1,000 for only $0.50/share today before the offer closes in the next few days</a>!</li>
</ul>
In an <a href="https://www.youtube.com/watch?v=-Oa8Xe-htBA">interview</a>, Errol Musk gave insight into how he feels about Elon's new position. He expressed mixed emotions, mostly around the potential impact on Elon's commitments to his many companies, including Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), SpaceX and X. According to Errol, having Elon in a government role is exciting but also brings some real concerns about his time.
<h2 class="wp-block-heading">Balancing Act for Elon Musk</h2>
Errol Musk acknowledged that Elon's new government role is significant but noted that Elon already has a lot on his plate. With his existing leadership positions, taking on a government role adds even more to an already busy schedule.
"Elon has a tremendous task on his hands," Errol said. "He has a couple hundred thousand employees and a lot of very serious things going on in his life, so he has to be available for all that he started … [he] can&#8217;t just walk away from things."
Trending: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a>
He added, "To have him sit in an office somewhere in Washington, waiting and twiddling his thumbs – no, no. He has to be called upon on a sort of consultancy basis." Errol made it clear that he's not entirely comfortable with Elon having to dedicate a lot of time to government work if it comes at the expense of his businesses. It would be a "big concern" if he had to step away from the board meetings and other company responsibilities to go to the government.
<h2 class="wp-block-heading">Why Elon Is Well-Suited for Government Efficiency</h2>
Errol Musk also praised his son's ability to improve efficiency, citing his experience in turning struggling businesses into highly productive and profitable entities. He highlighted Elon's <a href="https://www.benzinga.com/news/24/11/41698648/elon-musks-x-reportedly-hit-with-new-wave-of-layoffs-engineering-department-faces-major-cuts-amid-un">drastic staff cuts at X</a> after its acquisition, reducing the workforce from 8,500 employees to about 1,000 while still making the platform run better than before.
See Also: This rooftop wind turbine is taking on a market projected to reach over $900 billion by 2032 —<a href="https://www.benzinga.com/money/halcium"> With already over 40,000 users signing up to purchase, here's a chance to be an early investor today!</a>
"I can't think of anyone more suited to a role like this than Elon," Errol said. "He's always been frugal. As a young boy, he wanted to do things as cheaply, better and quicker than anyone else."
He suggested that <a href="https://www.benzinga.com/news/24/05/39039546/hr-expert-urges-elon-musk-to-revamp-management-practices-amid-criticism-of-teslas-hiring-and-firing">Elon's management style</a> could translate well into eliminating unnecessary expenses and improving productivity in government agencies. "People whose lives are being wasted in jobs that have no real productivity might be released into more productive employment and I think that's a very good thing," Errol added.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai-2"> here's how there's a limited time opportunity to invest at $1,000 for only $0.50/share before it closes in a few days.</a></li>
</ul>

Startups

TSLA

Elon Musk's Father Says It Would Be 'A Big Concern' If Elon Had To Step Away From Board Meetings At His Companies To 'Go To Government'

BMO Capital analyst Tamy Chen maintains George Weston (TSX:<a class="ticker" href="https://www.benzinga.com/stock/WN#TSX">WN</a>) with a Market Perform and raises the price target from C$220 to C$221.5.

TSX:WN

BMO Capital Maintains Market Perform on George Weston, Raises Price Target to C$221.5

BMO Capital analyst Ben Pham maintains TC Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRP#NYSE">TRP</a>) with a Market Perform and raises the price target from $66 to $70.

BMO Capital Maintains Market Perform on TC Energy, Raises Price Target to $70

Qualcomm CEO Says PC-Chip Sales Exceeding Expectations

RBC Capital analyst Steven Shemesh maintains Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) with a Outperform and lowers the price target from $52 to $46.

RBC Capital Maintains Outperform on Valvoline, Lowers Price Target to $46

<a href="https://www.bnnbloomberg.ca/business/international/2024/11/20/jj-merck-cut-jobs-in-china-as-local-competition-takes-toll/#:~:text=Both%20US%20drug%20giants%20have,diabetes%20unit%2C%20the%20people%20said.">https://www.bnnbloomberg.ca/business/international/2024/11/20/jj-merck-cut-jobs-in-china-as-local-competition-takes-toll/#:~:text=Both%20US%20drug%20giants%20have,diabetes%20unit%2C%20the%20people%20said.</a>
Johnson &amp; Johnson and Merck &amp; Co. are cutting jobs in China, as they face growing competition from domestic rivals resulting from Beijing's campaign to drive down medical costs.
Both US drug giants have laid off employees in China in recent days, according to people familiar with the matter who asked not to be identified discussing internal matters. The J&amp;J cuts mainly impacted a division that sells products used in surgery, while Merck scaled back in its diabetes unit, the people said.&nbsp;
Chinese media outlets, which were first to report the redundancies, cited the J&amp;J layoffs to be as much as a fifth of its mainland workforce. J&amp;J employs nearly 10,000 people across some 90 cities in China, according to its website.&nbsp;
J&amp;J "has recently implemented organizational changes to optimise our business operations" in the country, a company spokesperson told Bloomberg in an email. J&amp;J remains committed to the "critical and growing" China market, the spokesperson added.&nbsp;
Merck didn't immediately reply to a request for comment outside regular business hours.&nbsp;
Multinational drug and medical device makers are grappling with narrower profit margins in China, largely due to the country's system of having companies bid to supply drugs and devices to public hospitals — known as volume-based procurement (VBP). The program has seen global pharmaceutical companies lose hospital contracts for their top off-patent drugs and devices to cheaper local suppliers, essentially putting their sales team out of work in those categories.
The layoffs add to turmoil in the pharmaceutical market in China. Once seen as a big market opportunity for global drugmakers to expand, they've come under regulatory pressure on multiple fronts. AstraZeneca, which has seen China revenue growth slow due in part to losing hospital contracts for its off-patent medicines, is facing a criminal investigation into allegedly illegal sales practices which has ensnared its China chief.&nbsp;
In a recent earnings call, J&amp;J executives acknowledged a "disproportionate impact from VBP" thanks to its being the largest medtech company in China. The layoffs are the first major round of redundancies affecting the company's surgery division, a person familiar with the matter said, though layoffs in other departments have been ongoing for some time.&nbsp;
Meanwhile, Merck is set to face off against local suppliers for generic versions of two major diabetes drugs – Januvia and Janumet – in the latest round of VBP tender submissions.&nbsp;

Comments

AEye

AEye (LIDRW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga